ReviewBeilstein journal of nanotechnology2025
Enhancing the therapeutical potential of metalloantibiotics using nano-based delivery systems.
Review in Beilstein journal of nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A platinum butterfly effect: small changes turn an anticancer drug into a non-toxic metalloantibiotic with in vivo efficacy.npj antimicrobials and resistance · 2026Article
- Biomaterials Based on Bacteria for Cancer Clinical Therapy.Biomaterials research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid spread of antibiotic resistance has intensified the need for novel therapeutic strategies against multidrug-resistant bacterial infections. Metalloantibiotics present a promising alternative in combating resistant pathogens. However, the clinical application of metalloantibiotics is limited by their potential toxicity, instability, and lack of target specificity. Encapsulating metalloantibiotics in drug delivery systems, such as liposomes, nanoparticles, and polymeric carriers, could mitigate these challenges, enhancing their therapeutic index and enabling their precise, localized release. Recent reviews have outlined the key design parameters and clinical translation challenges associated with nanocarrier-based antimicrobial therapies, underscoring their relevance in overcoming bacterial resistance mechanisms [Xie, Y.; Liu, H.; Teng, Z.; Ma, J.; Liu, G.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.